Impact of Chemotherapy on Retroperitoneal Lymph Nodes in Ovarian Cancer

Anticancer Res. 2016 Apr;36(4):1815-24.

Abstract

Background: Complete cytoreduction is the most important prognostic factor in ovarian cancer. However, there exist conflicting data on whether the removal of microscopic tumor metastasis in macroscopically unsuspicious retroperitoneal lymph nodes is beneficial.

Patients and methods: Ovarian cancer tissues and tissues from lymph node metastasis of 30 patients with FIGO IIIC or IV disease undergoing neoadjuvant chemotherapy (NACT) were obtained and assessed using a validated regression score. Histopathological markers, size of largest tumor focus, and overall score were evaluated in lymph node and ovarian tissue. Regression and known prognostic factors were analyzed for influence on survival.

Results: No difference in the overall score between lymph nodes and ovarian tissue was shown, however, single parameters such as fibrosis and pattern of tumor infiltration, were significantly different.

Conclusion: The pattern of tumor regression in lymph nodes and ovarian tissue are of prognostic value. Lymph node dissection even of unsuspicious nodes should, therefore, be performed.

Keywords: Ovarian cancer; lymph nodes; neoadjuvant chemotherapy; tumor regression.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bridged-Ring Compounds / therapeutic use
  • Carboplatin / therapeutic use
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Female
  • Fibrosis
  • Gemcitabine
  • Humans
  • Lymph Node Excision
  • Lymph Nodes / drug effects*
  • Lymph Nodes / pathology
  • Lymphatic Metastasis
  • Middle Aged
  • Neoadjuvant Therapy*
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / pathology
  • Prognosis
  • Retroperitoneal Space
  • Taxoids / therapeutic use

Substances

  • Bridged-Ring Compounds
  • Taxoids
  • Deoxycytidine
  • taxane
  • Carboplatin
  • Gemcitabine